Accure Therapeutics
Financials
Estimates*
EUR | 2020 | 2021 |
---|---|---|
EBITDA | (1.1m) | (<1m) |
Profit | (2.1m) | (3.2m) |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
* | €7.6m | Series A | |
Total Funding | CAD11.4m |
Related Content
Recent News about Accure Therapeutics
EditAccure Therapeutics is a research and development pharmaceutical company that focuses on developing new treatments for Central Nervous System (CNS) diseases. The company takes a distinct approach to drug development, utilizing recent advances in neurobiology, neurodegeneration, and neuroinflammation to select relevant targets and develop drugs that can combat neurological diseases. Accure Therapeutics has been awarded a grant by ACCIÓ for their contributions to Parkinson's therapies. This grant demonstrates the company's commitment to finding new treatments for neurological diseases, and their dedication to making a difference in the lives of those affected by these conditions. Accure Therapeutics stands out from other businesses in the same industry by utilizing their understanding of the pathogenesis of brain diseases to develop treatments that can effectively combat neurological diseases. The company is committed to making a difference in the lives of those affected by neurological diseases, and their research and development efforts are focused on finding new treatments for these conditions.